Board of Directors
Jack was recently the Chief Commercial Officer of Accuri Cytometers (acquired by Becton Dickinson in 2011). Jack is a seasoned executive with a 30 year track record for marketing and selling life science instruments & consumables at top companies. Prior to joining Accuri in 2006, Jack was CEO of Amnis Corporation, a venture backed technology start-up developing high-end imaging flow cytometers. He also served as Chief Commercial Officer for Molecular Probes, Inc. (now a part of Life Technologies), the world leader in reagents for molecular biology and cell analysis. Prior to that, Jack was the Senior VP & General Manager of the Life Sciences Group at Orchid Biosciences. Jack was also a senior executive with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.
Timothy Harkins, PhD
Tim has served as President & CEO of Swift Biosciences since August 2015. He has 20 years of genomics experience, holding both R&D and commercial positions, as well as 60+ peer-reviewed publications that include more than 50 in the next-generation sequencing market. Prior to Swift Biosciences, Tim was responsible for new market development for Life Technologies on both their SOLiD™ and Ion Torrent™ next-generation sequencing platforms. As previous Director of Marketing at Roche, he was responsible for developing the market for the first next-generation sequencing platforms: 454 Life Sciences’ GS20 and GS FLX, Titanium, and Junior. During his free time, Tim is an avid skier and can often be found on the slopes at Grand Targhee, WY.
Dan is a Principal at Arboretum Ventures, a healthcare focused venture capital firm located in Ann Arbor, MI. In this role, Dan focuses on supporting Arboretum’s portfolio companies and leading new investments across the firm’s sectors of interest, with particular emphasis on life science tools. Since joining Arboretum in 2011, Dan has undertaken significant due diligence responsibilities to support more than a dozen of the firm’s new and follow-on investments, including Ebb Therapeutics, NeuMoDx, IntelliCyt, Rethink, Cardiac Dimensions, Strata Oncology, and SI-BONE. Dan’s portfolio company involvement has included serving on the board of directors for life science tools company IntelliCyt, until its $90 million acquisition by Sartorius in 2016.
Outside of Arboretum, Dan serves on the Oversight Committee for Wayne State University’s M-TRAC program and on the Investment Advisory Board for the Monroe-Brown Biomedical Seed Fund at the University of Michigan. Prior to joining Arboretum, Dan held finance roles at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan earned his BBA and MBA from the Ross School of Business at the University of Michigan.
Peter Kleinhenz has been actively involved in technology-based businesses as an entrepreneur, consultant, or professional investor for over 28 years and in the life sciences sector for over 25 years. His experience in life science includes investments in: devices, diagnostics, biologics, and healthcare services. He joined Fletcher Spaght Ventures as a Venture Partner in 2009. He represents Fletcher Spaght as a board member at Swift Biosciences and was a board member or advisor at Surgiquest, Inc. (acquired by Con Med, Inc.) and Cayenne Medical Inc.(acquired by Zimmer Biomet).
From 2001 to 2016 as a Managing Director, Peter represented CID Capital, Inc. as a board member or adviser in the following investments: AxioMed Spine Corporation, MedVantx, Inc., RedPath Integrated Pathology, Inc. (acquired by PDI, Inc.), EKOS Corporation (acquired by BTG International, Inc.), Renal Solutions (acquired by Fresenius Medical Care), QIS Solutions (acquired by ABeam Consulting), and Waterlink, Inc.
Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization-Life Sciences for Battelle Memorial Institute working in their medical device, pharmaceutical, and toxicology sectors. He was CEO and principal owner of Progenics Inc., a product development and pilot manufacturing company for medical products and industrial controls. He was part of the founding business team of Neoprobe Corporation, a biologic product and medical device company focused on cancer detection and therapy.
Peter received an MBA from Case Western Reserve University, a bachelor’s degree from Loyola University of Chicago, and is a Certified Public Accountant (inactive status) in Ohio.
Mark L. Lewis
Mark has participated in the life sciences industry for over 40 years. He has held research and development, commercial, and general management roles at leading organizations including Illumina, BD Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. Mark serves as a member of the Dean’s Leadership Council for Biological Sciences at University of California at San Diego. He is also a co-instructor for the Professional Pathways Course for PhDs and graduate students in life sciences at UCSD.
Most recently, Mark held Senior Vice President roles in Product Development, General Management, and Customer Support at Illumina, a leading supplier of systems for genetic analysis. During his time at Illumina, Mark directed the development of the HiSeq™ and MiSeq™ next-generation sequencing platforms and supporting reagents. Mark has also developed and commercialized platforms and technologies for genotyping, flow cytometry, molecular biology, PCR, high content screening, and confocal imaging. Mark earned a Bachelor of Arts in Biology from University of California at San Diego.
Vladimir Makarov, PhD
Vladimir has a track record of developing novel research and diagnostic methods and tools. His experience spans more than 30 years in cutting edge molecular biology and life science research, with broad expertise in different fields of science including physics, molecular biology, genomics, and molecular diagnostics. Vladimir has authored more than 30 issued and pending patents and 60 scientific publications. He has co-founded 2 biotech start-ups, leading to development and commercialization of more than 10 different products in the research tools and diagnostics space. Prior to Swift, Vladimir served as Chief Scientific Officer of Rubicon Genomics, and was the key inventor of Rubicon products. Vladimir was responsible for creating Rubicon’s product vision, research and development, and intellectual property management.
Vladimir received his PhD in Physics and Mathematics from St. Petersburg University and has held senior scientist positions at the University of Michigan (Ann Arbor) and the Institute of Molecular Biology (Moscow).
Dan Watkins, PhD
Dan is a Managing Director and co-founder of the Mercury Fund (Houston). He has experience in founding and managing start-up companies in both the bioscience and advanced materials sectors. Prior to co-founding the Mercury Fund, Dan was the founder and Managing Partner of A3 Associates, a Houston-based venture firm focused on seed-stage investments in university and research center-based technology transfer opportunities. In this capacity, Dan co-founded DNAtrix, Nanospectra Biosciences and X-EMI. Prior to A3 Associates, Dan was a VP at Schnitzius & Vaughan, a Houston-based investment banking firm. Dan currently serves on the advisory boards of BioHouston, the Gulf Coast Regional Center for Innovation and Commercialization for the Texas Emerging Technology Fund, the Rice Alliance for Technology & Entrepreneurship, and Wayne State University’s Center for Molecular Medicine and Genetics. Dan is also a co-founder of the Rice Alliance for Technology & Entrepreneurship.
Dan received his B.S. in Materials Science and Engineering from Rice University and his M.S. and Ph.D. in Materials Science and Engineering from Carnegie Mellon University.
Walt has more than 40 years experience in leading organizations. For the first 36 years, he held senior positions at four public companies: BF Goodrich, The Budd Company, The Henley Group and Champion Enterprises. As Chair and CEO of Champion (Fortune 500) Walt was recognized by Fortune as a “Superstar” and by the Harvard Business School as one of the 19 top business leaders of the 1990s. While at these four companies he completed 23 different turnarounds and over 75 mergers and acquisitions. Since 2003 Walt has focused on entrepreneurial start-ups, including as a lead investor and Director for Accuri Cytometers (acquired by Becton, Dickinson in 2011). He has led and assisted over 40 entities to raise more than $45M in capital. In addition to Swift, Walt is currently on the board of GuidePoint Systems, Weathershield and nanocerox.—all based in Michigan. He is also Chair of Eagle River Homes, a director at NRG Energy (NYSE:NRG, Fortune 300) and ZETA Communities LLC, and a Trustee for Muskingum University.
Walt received a BA in History and Economics from Muskingum University, his MBA in Marketing and Management from Penn State University and an honorary doctorate in Public Service from Muskingum University.